Pfizer signed a license agreement with AI biologics startup Chai Discovery on June 4, 2026, gaining access to Chai-3, a model the company says doubled the success rate of therapeutic antibody design over its predecessor.
The FDA announced on April 28, 2026 a pilot with AI firm Paradigm Health covering trials run by Amgen and AstraZeneca, with the agency's chief AI officer estimating real-time data flows could shave 20 to 40 percent off trial timelines.
The VA has deployed ambient AI scribes to all primary care teams nationwide, after passing over Microsoft's Nuance in favor of contracts with Abridge and a smaller rival, Knowtex.
Epic said 85% of its healthcare customers are now live on generative AI tools as it rolled out native ambient documentation and previewed a new AI-native interface called Ergo at its 2026 user conference.
A Cleveland Clinic study of 4,000 clinicians found 60% said an ambient AI scribe increased their likelihood of staying in practice, with 97% reporting overall satisfaction with the tool.
Wood Mackenzie projects utilities will build only about 28% of the 1,066 gigawatts requested for AI data centers, with the rest amounting to duplicative 'phantom load' that could distort grid planning.
Clair Health raised $11.6 million led by Khosla Ventures to build a wrist wearable that uses machine learning to infer estrogen, progesterone, LH and FSH levels without blood tests, launching in November.
A University of Toronto-led study finds that of 1,357 FDA-cleared AI medical devices, only three have ever been tested on whether they improve patient outcomes like survival or hospitalization.
Abridge is expanding from an ambient AI scribe into billing and clinical trial screening, backed by an Eli Lilly equity investment and a new NVIDIA-co-developed clinical foundation model.
A Nature Medicine study found OpenAI's ChatGPT Health under-triaged more than half of emergency-care cases and showed inverted suicide-risk alerts, testing the tool across 960 clinical interactions.